BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma

Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...

July 27, 2026 | News

The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028

There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...

July 24, 2026 | Analysis

Discount or Validation? Western Pharma’s Appetite for Chinese Assets

There is a number that has stopped being a niche statistic for Asia-watchers and started reshaping where the global drug industry shops. The average upfron...

July 24, 2026 | Analysis

Top 26 Companies Leading Sustainable Biopharma Practices in 2026

Sustainability has stopped being a side conversation in the pharmaceutical industry. In 2026 it sits at the centre of how the sector defines leadership. Th...

July 23, 2026 | Analysis

The Bioreactors Are Ours. The Consumables Are Not.

A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...

July 22, 2026 | Analysis

Rege Nephro Raises $10.6M to Advance iPS Cell-Based Kidney Disease Pipeline

inancing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline Rege Nephro Co., Ltd. ("Rege Nephr...

July 22, 2026 | News

Poland and Taiwan Turn Biotech Dialogue into Partnership at BIO Asia–Taiwan 2026

Poland and Taiwan moved to strengthen their biotechnology relationship at the Poland–Taiwan Biotechnology Forum, held on 17 July during BIO A...

July 20, 2026 | News

Canada and Taiwan Build New Bridges Across AI, Advanced Therapeutics and Precision Health

As biotechnology increasingly converges with artificial intelligence, advanced therapeutics and data-driven healthcare, the next generation of inno...

July 20, 2026 | News

Why Korea, Why Now? Korean Biotech Looks to Taiwan as Asia’s Next Partnership Frontier

Korea’s biotechnology industry is entering a new phase of global ambition. Having established significant capabilities across biopharmaceutical manuf...

July 20, 2026 | News

Japan Looks Beyond Its Borders to Build the Next Generation of Biotech Innovation

Japan’s biotechnology sector is entering a new phase in which scientific strength alone may no longer determine success. As drug development becomes ...

July 20, 2026 | News

Malaysia Positions Biotechnology as a Bridge Between Asian Innovation and Global Markets

As Asia’s biotechnology sector moves from scientific capability towards commercial scale, Malaysia is positioning itself as an increasingly i...

July 20, 2026 | News

India’s Life Sciences Proposition Expands from Global Scale to Strategic Innovation

India’s position in the global life sciences economy has long been anchored in scale — from active pharmaceutical ingredients (APIs) and generi...

July 20, 2026 | News

Stay Connected